针对MTAP阴性癌症的潜力和挑战超出了合成致死性
Chandler Bray1, Cristina Balcells1, Iain A McNeish2
1Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery & Cancer, Imperial College London, London, United Kingdom.
Frontiers in oncology
|October 5, 2023
概括
大约15%的癌症会失去瘤抑制基因CDKN2A和MTAP. 失去MTAP会激活PRMT5,这是癌症治疗的目标. 了解PRMT5抑制剂是有效治疗的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 15%的癌症涉及9p21.3位点,影响瘤抑制剂CDKN2A和MTAP.
- 失去MTAP会增加甲基腺素 (MTA),抑制蛋白质氨酸甲基转移酶5 (PRMT5).
- PRMT5通过氨酸甲基化调节基因转录,使其成为治疗点.
研究的目的:
- 讨论在癌症治疗中针对MAT2A/PRMT5轴的理由和方法.
- 评估理解MAT2A/PRMT5抑制机制的局限性.
- 确定最大限度地发挥药物潜力的挑战,并探索新的组合疗法.
主要方法:
- 对癌症中MAT2A/PRMT5轴的当前文献的综述.
- 分析PRMT5活动的下游影响因素.
- 治疗策略和临床开发挑战的评估.
主要成果:
- 准MAT2A/PRMT5在MTAP阴性癌症中显示出合成致死性的前景.
- 由于对药物机制的不完全理解,抑制剂的临床开发面临挑战.
- 下游的PRMT5效应器可以确定对抑制的敏感性.
结论:
- 针对MAT2A/PRMT5轴是一个有前途的癌症治疗策略.
- 需要进一步的研究来克服临床开发中的挑战,并了解药物机制.
- 识别PRMT5下游效应因子可以引导新型组合疗法超越合成致死性.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
544
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K


